Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Stifel lowered its price target on Vertex Pharmaceuticals (NASDAQ:VRTX) to $445 from $455 while maintaining a Hold rating on the stock. The biotech giant currently trades at $419.21, with analyst targets ranging from $330 to $603, suggesting potential upside of 12% based on consensus estimates.
The research firm cited an in-line performance for Vertex’s cystic fibrosis business, with Alyftrek outperforming expectations, but noted that newer products Journavx and Casgevy missed targets as their adoption continues at a gradual pace. InvestingPro data shows Vertex achieved 10.3% revenue growth over the last twelve months, with over $11.7 billion in total revenue.
Stifel indicated that Vertex’s commercial business now shows less quarter-to-quarter variance, suggesting the stock may depend more on pipeline developments rather than consistent earnings beats for significant upside potential. The company maintains strong financial fundamentals with an "GREAT" overall financial health score according to InvestingPro, operating with moderate debt levels and liquid assets exceeding short-term obligations.
Investor attention has shifted toward Vertex’s kidney portfolio, particularly povetacicept, a dual BAFF/APRIL-antagonist, which has upcoming clinical catalysts including an investor event at ASN this weekend featuring longer-term follow-up data in IgAN and PMN.
The firm noted that while povetacicept data is expected to be positive, the key question remains whether results will demonstrate clear advantages over competing treatments, as other pipeline components including the APOL1 program gain focus.
In other recent news, Vertex Pharmaceuticals reported third-quarter 2025 results that exceeded analysts’ expectations, with earnings per share (EPS) of $4.80, beating the forecast of $4.57. The company’s revenue reached $3.08 billion, slightly surpassing the anticipated $3.05 billion. Despite these strong results, Vertex’s newer products showed mixed performance against analyst forecasts. Cantor Fitzgerald maintained its Overweight rating on Vertex, citing strong Trikafta sales and lower taxes as key contributors to the earnings beat. However, BMO Capital lowered its price target for Vertex to $24.00 from $30.00, citing growth challenges that are affecting annual recurring revenue. Bernstein also adjusted its price target to $466.00 from $471.00, highlighting uncertainties related to the ramp-up of Alyftrek and Journavx. These developments reflect a complex landscape for Vertex as it navigates both impressive earnings and challenges in its growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.